Last Update Time:
12-Mar-2025 09:56:14
ISIN:
INE685A01028
Sector:
Healthcare
Symbol:
TORNTPHARM
Torrent Pharmaceuticals Limited
₹3,072.05
₹14.10
(0.46%)
▲
Prev. Close
₹3,057.95
Open
₹3,085.50
Close
₹0.00
Range
₹2,918.45 - ₹3,225.65
High
₹3,085.50
Low
₹3,031.80
Ind. Close
₹0.00
VWAP
₹3,053.98
The current stock price of Torrent Pharmaceuticals Limited is ₹3,072.05, with a target price range between ₹2,918.45 and ₹3,225.65. The stock has experienced a price change of ₹14.10 (0.46%), reflecting recent market volatility.
Today's opening price was ₹3,085.50, while the previous close stood at ₹3,057.95.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Torrent Pharmaceuticals Limited Price Chart
Torrent Pharmaceuticals Limited Pre Open Market Overview: 12-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 3085.5
- Previous Close Price: 3057.95
- Change: 27.55%
- Total Traded Volume: 155
- Total Buy Quantity: 1,865
- Total Sell Quantity: 596
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 3,057.95 | 19.00 | 0.00 |
| 3,060.00 | 70.00 | 0.00 |
| 3,066.00 | 3.00 | 0.00 |
| 3,077.50 | 42.00 | 0.00 |
| 3,080.00 | 10.00 | 0.00 |
| 3,085.50 | 0.00 | 45.00 |
| 3,085.65 | 0.00 | 3.00 |
| 3,085.75 | 0.00 | 22.00 |
| 3,085.80 | 0.00 | 14.00 |
| 3,085.90 | 0.00 | 9.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 3,071.05 | 10 | 3,072.45 | 19 |
| 3,071.00 | 3 | 3,072.95 | 9 |
| 3,070.95 | 1 | 3,073.10 | 1 |
| 3,070.85 | 2 | 3,073.30 | 1 |
| 3,070.80 | 1 | 3,073.45 | 2 |
Total Buy Quantity: 1865
Total Sell Quantity: 596
Shareholding Patterns of Torrent Pharmaceuticals Limited
Key Trade Statistics of Torrent Pharmaceuticals Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.19 |
| Traded Value (₹ Cr.) | 5.68 |
| Total Market Cap (₹ Cr.) | 103,972.13 |
| Free Float Market Cap (₹ Cr.) | 28,821.78 |
| Impact cost | 0.03 |
| Quantity Traded | 275,298.00 |
| Deliverable Quantity | 194,899.00 |
| % of Quantity to Traded | 70.8 |
| Security VaR | 9.25 |
| Index VaR | N/A |
| VaR Margin | 9.25 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 12.75 |
| Face Value | 5 |
Key Price Statistics of Torrent Pharmaceuticals Limited
The 52-week high for Torrent Pharmaceuticals Limited was ₹3,590.70, recorded on 09-Oct-2024. On the other hand, the 52-week low stands at ₹2,487.80, with the lowest value recorded on 19-Mar-2024.
The upper band for trading is ₹3,363.70, and the lower band is ₹2,752.15. The price band is No Band%.
The stock's daily volatility stands at 1.48, while the annualized volatility is 28.28. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (09-Oct-2024) | 3,590.70 |
| 52 Week Low (19-Mar-2024) | 2,487.80 |
| Upper Band | 3,363.70 |
| Lower Band | 2,752.15 |
| Price Band (%) | No Band |
| Daily Volatility | 1.48 |
| Annualised Volatility | 28.28 |
| Tick Size | 0.05 |
Key Securities Statistics of Torrent Pharmaceuticals Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 25-Nov-2002 |
| Adjusted P/E | 55.58 |
| Symbol P/E | 55.58 |
| Index | NIFTY NEXT 50 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Torrent Pharmaceuticals Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Torrent Pharmaceuticals Limited
| Subject | Date |
|---|---|
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 27-Feb-2025 |
| Resignation | 27-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 21-Feb-2025 |
| Action(s) initiated or orders passed | 17-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 14-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 08-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 07-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 31-Jan-2025 |
Corporate Actions of Torrent Pharmaceuticals Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 5 | Interim Dividend - Rs 26 Per Sh | 31-Jan-2025 |
| 5 | Dividend - Rs 6 Per Share | 21-Jun-2024 |
| 5 | Interim Dividend - Rs 22 Per Share | 12-Feb-2024 |
| 5 | Dividend - Rs 8 Per Share | 23-Jun-2023 |
| 5 | Interim Dividend - Rs 14 Per Share | 03-Feb-2023 |
| 5 | Bonus 1:1 | 08-Jul-2022 |
| 5 | Interim Dividend - Rs 25 Per Share | 02-Feb-2022 |
| 5 | Dividend - Rs 15 Per Share | 17-Jun-2021 |
| 5 | Interim Dividend - Rs 20 Per Share | 15-Feb-2021 |
| 5 | Interim Dividend - Rs 17 Per Share Special Dividend - Rs 15 Per Share | 18-Mar-2020 |
| 5 | Dividend Rs 4 Per Share | 13-Jun-2019 |
| 5 | Interim Dividend - Rs 13 Per Share | 06-Feb-2019 |
| 5 | Dividend- Rs 5 Per Share | 18-Jun-2018 |
| 5 | Interim Dividend Rs 9/- Per Share (Purpose Revised) | 15-Feb-2018 |
| 5 | Dividend - Rs 4/- Per Share | 19-Jun-2017 |
| 5 | Interim Dividend Rs 10/- Per Share (Purpose Revised) | 10-Feb-2017 |
| 5 | Interim Dividend - Rs 15/- Per Share (Purpose Revised) | 16-Mar-2016 |
| 5 | Interim Dividend - Rs 20/- Per Share (Purpose Revised) | 11-Feb-2016 |
| 5 | Dividend - Rs 6.25/- Per Share | 15-Jun-2015 |
| 5 | Interim Dividend - Rs 5/- Per Share (Purpose Revised) | 02-Feb-2015 |
Board Meetings of Torrent Pharmaceuticals Limited
Financial Results of Torrent Pharmaceuticals Limited
Company Directory of Torrent Pharmaceuticals Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.torrentpharma.com | Registered Office | Torrent House, Off. Ashram Road, Navarangpura | AHMEDABAD |
| www.torrentpharma.com | Transfer Agent | KFin Technologies Limited Selenium Tower, Tower B, Plot No. 31 & 32, Financial District, Gachibowli, Nanakramguda, Hyederabad | HYDERABAD |
Insider Trading of Torrent Pharmaceuticals Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Jinesh Shah, Designated Person (in capacity of trustee of Jinesh Trust) | 0 | Buy |
| 7(2) | Shailesh Haribhakti | 10058040 | Pledge |
| 7(2) | Shailesh Haribhakti | 19936893 | Buy |
| 7(2) | Shailesh Haribhakti | 2944025 | Buy |
| 7(2) | Shailesh Haribhakti | 5005018 | Buy |
| 7(2) | Shailesh Haribhakti | 1997986 | Buy |
| 7(3) | Harish Guttikar | 1086400 | Buy |
| 7(3) | Harish Guttikar | 555600 | Sell |
| 7(2) | Karan Shah | 257562 | Buy |
| 7(2) | Karan Shah | 2329360 | Buy |
| 7(2) | Karan Shah | 257700 | Sell |
| 7(2) | Karan Shah | 2313319 | Sell |
| 7(2) | Ameera Shah | 2664000 | Sell |
| 7(2) | Ameera Shah | 1993738 | Buy |
| 7(2) | Shailesh Haribhakti | 8391600 | Sell |
| 7(2) | Torrent Private Limited | 35850726984 | Buy |
| 7(2) | Anita Sudhir Mehta | 8574355368 | Sell |
| 7(2) | Sudhir Uttamlal Mehta HUF | 2406049380 | Sell |
| 7(2) | Sudhir Uttamlal Mehta | 8245271676 | Sell |
| 7(2) | Samir Uttamlal Mehta HUF | 2913939900 | Sell |
Annual Reports of Torrent Pharmaceuticals Limited
Investor Complaints of Torrent Pharmaceuticals Limited
Event Calendar of Torrent Pharmaceuticals Limited
| Purpose | Details |
|---|---|
| Bonus/Sub-division | To consider, inter-alia, sub-division of the equity shares of the company and issuance of bonus shares to the equity shareholders of the company. |
| Financial Results | To consider, inter alia, Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on June 30, 2010. |
| Results/Others | To consider, inter alia, Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company as per Clause 41 of the Listing Agreement for the quarter and half year ended on September 30, 2010. |
| Results/Others | To consider, inter alia, Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company as per Clause 41 of the Listing Agreement for the quarter and nine months ended on December 31, 2010. |
| Results/Dividend | To consider, inter alia, the Audited Financial Results of the Company for the year ended on March 31, 2011 and recommendation of dividend for the financial year 2010-11. |
| Financial Results | To consider, inter alia, the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis for the quarter ended June 30, 2011. |
| Financial Results | To consider, inter alia, the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2011. |
| Results/Dividend | To consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results ( with limited review ) on Consolidated basis of the Company for the quarter ended and nine months ended on December 31, 2011. In the meeting, Board would also consider payment of Interim Dividend for the year 2011-12. |
| Results/Dividend | To consider, inter alia, the Audited Financial Results for the year ended March 31, 2012 and recommendation of final dividend for the said year. |
| Financial Results | Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the Quarter ended June 30, 2012. |
| Financial Results | Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the second quarter and half year ended on September 30, 2012. |
| Results/Dividend | To consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results ( with limited review ) on Consolidated basis of the Company for the quarter ended and nine months ended on December 31, 2012. In the meeting, Board would also consider payment of Interim Dividend for the year 2012-13. |
| Results/Dividend | To consider, inter alia, the Audited Financial Results of the Company for the year ended on March 31, 2013 and recommendation of dividend for the said year. |
| Results | Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the Quarter ended June 30, 2013. |
| Results | Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2013. |
| Results | Inter-alia, to consider and approve the Audited Financial Results on Standalone basis and unaudited Financial Results (with limited review) on consolidated basis of the Company for quarter and nine months ended December 31, 2013. Further the Company has informed that as per the provisions of the Insider trading code of the Company, the trading window will remain closed between January 01,2014 to January 22, 2014 (Board meeting for, inter-alia, considering above results being held on January 21, 2014.) |
| Results/Dividend | The Company had informed the Exchange regarding Board Meeting to be held on January 21, 2014 , inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on December 31, 2013.The company has now informed the Exchange that the Board would also consider payment of Interim Dividend for the year 2013-14. (purpose revised) |
| Results | inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on December 31, 2013. Further as per the provisions of the Insider Trading Code of the Company, the trading window will remain closed between January 01, 2014 to January 22, 2014. |
| Results/Dividend | The Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on May 09, 2014 To consider ,inter alia, the Audited Financial Results for the year ended on March 31, 2014. Further as per the provisions of the Insider Trading Code of the Company, the trading window will remian closed between April 01, 2014 to May 10, 2014."The company has provided details of trading window period as per Prohibition of Insider Trading Regulations, 1992 issued by SEBI wherein when the trading window is closed, the employees/directors shall not trade in the company s securities in such period".The Company has now informed the Exchange that in the above meeting the Board would recommend the Final Dividend for the year ended on March 31, 2014.(purpose revised) |
| Results | To consider ,inter alia, the Audited Financial Results for the year ended on March 31, 2014. Further as per the provisions of the Insider Trading Code of the Company, the trading window will remian closed between April 01, 2014 to May 10, 2014. "The company has provided details of trading window period as per Prohibition of Insider Trading Regulations, 1992 issued by SEBI wherein when the trading window is closed, the employees/directors shall not trade in the company s securities in such period". |
| Results | Inter-alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for quarter ended June 30, 2014. Further the Company has informed that as per the provisions of the Insider Trading Code of the Company, the trading window will remain closed between July 01, 2014 to July 31, 2014 (Board meeting for, inter-alia, considering above results being held on July 30, 2014). |
| Results | Inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2014. Further, as per the provisions of the Insider Trading Code of the Company, the trading window will remain closed between October 01, 2014 to November 06, 2014 (Board meeting for, inter alia, considering above results being held on November 05, 2014). |
| Results/Dividend | The Company had Informed Exchange that the meeting of the Board of Directors of the Company to be held on January 28, 2015 for, inter alia, considering and approving the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on December 31, 2014. The Company has now informed Exchange that the Board would also consider payment of lnterim Dividend for the year 2014-15. |
| Results | inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on December 31, 2014. |
| Results | inter alia, to consider the Audited Financial Results for the year ended on March 31, 2015. |
| Results | Inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on June 30, 2015. |
| Results | inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2015. |
| Results/Dividend | Inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited Review) on Consolidated Basis of the Company for the quarter and nine months ended on December 31, 2015. The Board would also consider payment of Interim Dividend for the year 2015-16. |
| Dividend | To consider inter-alia the proposal for declaration of Second Interim Dividend, if any, for the year 2015-16. |
| Issue of Securities | To consider inter-alia the proposal for raising of funds by way of: a) Issue of Equity shares including Convertible Bonds/Debentures through Qualified Institutional Placements (QIP) and/ or Depository Receipts and I or any other modes. b) Issue of Unsecured I Secured Redeemable Non-Convertible Debentures/ Bonds by way of Private Placement. |
| Results | to consider inter-alia the Audited Financial Results for the year ended on March 31, 2016. |
| Results | To consider inter-alia the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on June 30, 2016. Further Company would like to inform that, as per the provisions of the Code of Conduct to Regulate, Monitor and Report Trading by Insiders of the Company, the trading window will remain closed between July 13, 2016 to July 29, 2016. |
| Results | To consider inter-alia the Audited Financial Results on Standalone basis and Unaudited Financial Result (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2016. |
| Results/Dividend | Inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on December 31, 2016. Further the Board would also consider payment of Interim Dividend for the year 2016-17. |
| Results/Dividend | Inter alia to consider and approve the Audited Financial Results for the year ended on March 31, 2017 and to consider for recommendation of final dividend for the year ended March 31, 2017. The Board would also consider the proposal for taking the enabling resolutions for raising of funds by way of Issue of Unsecured / Secured Redeemable Non-Convertible Debentures/ Bonds by way of Private Placement. If approved by the Board of Directors, the said item will be placed Shareholders' approval in the ensuing Annual General Meeting. |
| Results | inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results ( with limited review) on Consolidated basis of the Company for the quarter ended on June 30, 2017. |
| Results | inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results ( with Limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2017. |
| Raising of Funds | to consider inter-alia the following: 1) Issue of Equity shares including Convertible Bonds/Debentures through Qualified Institutional Placement ( QIP) and /or Depository Receipts or any other modes. 2) Issue of Unsecured/Secured Redeemable Non-Convertible Debentures/Bonds by way of private placement. |
| Results/Dividend | inter alia to consider and approve the Financial Results on Standalone and Consolidated basis of the Company for the quarter and nine months ended on December 31, 2017. 2) In the above meeting, the Board would also consider payment of Interim Dividend for the year 2017-18. 3) As per Regulation 42 of the Listing Regulations, the Company has fixed February 19, 2017,as the Record date for the purpose of payment of said Interim dividend, if declared by the board at their aforesaid meeting, payable to those shareholders whose name appears on the Register of Members or on records of National Securities Depositories Limited or Central Depositories Services ( India) Limited as beneficial owners as on said record date. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results/Dividend/Fund Raising | To consider and approve the financial results for the period ended December 31, 2018, dividend and Fund Raising |
| Financial Results/Dividend/Fund Raising | To consider and approve the financial results for the period ended December 31, 2018, dividend and Fund Raising |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and final dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results/Dividend/Fund Raising | To consider and approve the financial results for the period ended December 31, 2019, dividend and Fund Raising |
| Dividend | To consider dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2020 and dividend |
| Financial Results/Dividend/Fund Raising | To consider and approve the financial results for the period ended March 31, 2021, dividend and Fund Raising |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2021 and dividend |
| Bonus | Torrent Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 25-May-2022 to consider Bonus |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended December 31, 2022, dividend and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2023, dividend and other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 We would like to inform you that a meeting of the Board of Directors will be held on Monday, 23-Oct-23, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-23. |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended December 31, 2023, dividend and other business matters |
| Financial Results/Dividend/Fund Raising | To consider and approve the financial results for the period ended March 31, 2024, dividend and Fund Raising |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2024 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended December 31, 2024, dividend and other business matters |
Share Transfers of Torrent Pharmaceuticals Limited
Voting Results of Torrent Pharmaceuticals Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 23-JUL-2024 | AGM | To receive, consider and adopt the Standalone Financial Statements as at 31st March, 2024 including the Audited Balance Sheet as at 31st March, 2024, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereon. |
| 23-JUL-2024 | AGM | Approval for enhancement of limit for the Loan, Guarantee and Investment by the Company under Section 186 of the Companies Act, 2013. |
| 23-JUL-2024 | AGM | Remuneration to Non-Executive Directors (NEDs). |
| 23-JUL-2024 | AGM | Appointment of Jinal Mehta as Non-Executive Non-Independent Director of the Company. |
| 23-JUL-2024 | AGM | Re-appointment of Samir Mehta as Executive Chairman and Fixation of Remuneration. |
| 23-JUL-2024 | AGM | Issuance of Equity Shares Including Convertible Bonds / Debentures. |
| 23-JUL-2024 | AGM | Ratification of Remuneration of Cost Auditors of the Company for the year 2024-25. |
| 23-JUL-2024 | AGM | Jinesh Shah (holding DIN: 00406498), a director, who retires by rotation at this Annual General Meeting and who has expressed his unwillingness for reappointment, be not re-appointed and the resulting vacancy be not filled up and the number of directors be reduced accordingly. |
| 23-JUL-2024 | AGM | To confirm the payment of interim dividend of Rs 22.00 per equity share of fully paid up face value of Rs. 5.00 each already paid during the financial year ended 31st March, 2024 and to declare final dividend of Rs. 6.00 per equity share of fully paid up face value of ` 5.00 each for the financial year ended on 31st March, 2024. |
| 23-JUL-2024 | AGM | To receive, consider and adopt the Consolidated Financial Statements as at 31st March, 2024 including the Audited Balance Sheet as at 31st March, 2024, the Statement of Profit and Loss for the year ended on that date and reports of the Auditors thereon. |
| 26-NOV-2023 | Postal Ballot | Appointment of Shaan Mehta, a relative of Directors as an Executive of the Company |
| 07-AUG-2023 | AGM | To receive, consider and adopt the Standalone and Consolidated Financial Statements as at 31st March, 2023 including the Audited Balance Sheet as at 31st March, 2023, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereon. |
| 07-AUG-2023 | AGM | Appointment of Nikhil Khattau as an Independent Director of the Company. |
| 07-AUG-2023 | AGM | Alteration of Articles of Association of the Company. |
| 07-AUG-2023 | AGM | Issuance of Equity Shares including Convertible Bonds / Debentures. |
| 07-AUG-2023 | AGM | Ratification of remuneration of Cost Auditors of the Company for the year 2023-24. |
| 07-AUG-2023 | AGM | To appoint a Director in place of Samir Mehta (holding DIN 00061903), Director, who retires by rotation, and being eligible, offers himself for re-appointment. |
| 07-AUG-2023 | AGM | To confirm the payment of interim dividend of Rs. 14.00 per equity share of fully paid up face value of Rs. 5.00 each already paid during the financial year ended 31st March, 2023 and to declare final dividend of Rs. 8.00 per equity share of fully paid up face value of Rs. 5.00 each for the financial year ended on 31st March, 2023. |
| 08-SEP-2022 | Postal Ballot | Appointment of Manish Choksi as an Independent Director of the Company |
| 08-SEP-2022 | Postal Ballot | Appointment of Aman Mehta as Director and Whole-Time Director of the Company and fixation of remuneration |
FAQs on Torrent Pharmaceuticals Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.